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Abstract
UDP-glucose (UDPG) and derivatives are naturally-occurring agonists of the Gi protein-coupled
P2Y14 receptor, which occurs in the immune system. We synthesized and characterized
pharmacologically novel analogues of UDPG modified on the nucleobase, ribose, and glucose
moieties, as the basis for designing novel ligands in conjunction with modeling. The recombinant
human P2Y14 receptor expressed in COS-7 cells was coupled to phospholipase C through an
engineered Gα-q/i protein. Most modifications of the uracil or ribose moieties abolished activity;
this is among the least permissive P2Y receptors. However, a 2-thiouracil modification in 15
(EC50 49 ± 2 nM) enhanced the potency of UDPG (but not UDP-glucuronic acid) by 7-fold. 4-
Thio analogue 13 was equipotent to UDPG, but S-alkylation was detrimental. Compound 15 was
docked in a rhodposin-based receptor homology model, which correctly predicted potent agonism
of UDP-fructose, UDP-mannose, and UDP-inositol. The hexose moiety of UDPG interacts with
multiple H-bonding and charged resides and provides a fertile region for agonist modification.
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Introduction
The nucleotide-activated P2 receptors occur in two subfamilies of plasma membrane
receptors. P2Y receptor subtypes include eight members, the P2Y1, P2Y2, P2Y4, P2Y6,
P2Y11, P2Y12, P2Y13, and P2Y14 receptors, which couple to G proteins. The seven subtypes
of ligand-gated cation channels that comprise the P2X receptor subfamily are denoted P2X1-
P2X7. All of these subtypes have been cloned and functionally characterized.1–10 The family
of P2Y receptors can be divided into two subgroups. A P2Y1-like subgroup (P2Y1, P2Y2,
P2Y4, P2Y6, P2Y11) is Gq-coupled and stimulates phospholipase C (PLC), and a P2Y12-like
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subgroup (P2Y12, P2Y13, P2Y14) is Gi coupled and inhibits adenylyl cyclase.11 P2Y
receptors are distributed in a broad range of tissues and are of interest as therapeutic targets,
including antithrombotic therapy, modulation of the immune system and cardiovascular
system, inflammation, pain, diabetes, and treatment of cystic fibrosis and other pulmonary
diseases.12–15 P2X receptors are activated principally by adenine nucleotides, and P2Y
receptors are activated by adenine and/or uracil nucleotides. For example, the P2Y2 receptor
is activated by both uridine 5′-triphosphate (UTP) and adenosine 5′-triphosphate (ATP), the
P2Y4 receptor by UTP, and the P2Y6 receptor by uridine 5′-diphosphate (UDP).16
The P2Y14 receptor is distributed in various tissues including placenta, adipose, stomach,
intestine, brain, spleen, thymus, lung, and heart.3 Potent and selective ligands, currently
lacking, are needed for pharmacological studies. UDP-glucose (1, UDPG), UDP-galactose
(2), and UDP-N-acetylglucosamine (4a) are naturally-occurring agonists of the P2Y14
receptor (Chart 1). The precise physiological function of the P2Y14 receptor has not yet been
clearly established, although it appears to be involved in immune function.17 In contrast to
other P2Y receptors, the P2Y14 receptor is not activated by uridine 5′-di- or triphosphates or
by adenine nucleotides.21 Extracellular release of UDPG has been demonstrated, and UDPG
does not activate any other P2Y receptor.17–23 The SAR (structure activity relationship) of
synthetic nucleotides for activation of the human P2Y14 receptor has not previously been
probed in a systematic fashion. Thus, we synthesized novel analogues of UDPG and
characterized their pharmacological activities at the recombinant human P2Y14 receptor.
The nucleobase, ribose, and glucose moieties were modified in this study. Molecular
modeling was carried out to predict sites of interaction of the ligands with the P2Y14




Analogues of UDPG (1) with modifications in the ribose ring, uracil moiety, and sugar
moiety as well as dinucleotides (Table 1), were synthesized. The ribose ring was modified
by removal of the hydroxyl group at the 2′ position 5 and replacement of the hydroxyl at the
2′ position with various functional groups, 6 – 8, 10, and 11. The hydroxyl group at the 3′
position was also modified in compounds 9 and 10. Replacement of the ribose ring with a
2′-deoxy (S)-methanocarba bicyclic ring24 (12) also was performed. The uracil ring was
modified at the 2 and 4 positions, with the synthesis of 4-thiouridine-5′-diphosphoglucose
(13) and 2-thiouridine-5′-diphosphoglucose (15),25 and at the 5 position, with iodide (16)
and fluoride (24). Sugar-modified compounds (25-27) were synthesized with commercially
available sugar monophosphates. Dinucleotides (29) were obtained as byproducts during the
synthesis of UDPG analogues and of CDP-glucose 19. All the nucleotide analogues were
prepared in their ammonium or triethylammonium salt form according to the methods
shown in Schemes 1 – 3 and tested in functional assays of the P2Y14 receptor (Table 1). The
nucleotide analogues were characterized using HPLC, nuclear magnetic resonance (1H
NMR, 31P NMR), and high-resolution mass spectrometry.
The nucleoside-5′-diphosphoglucose derivatives were obtained by the following methods.
5′-Monophosphorylation by reaction of the nucleoside with phosphorous oxychloride
provided the nucleoside 5′-monophosphate analogues 36 – 40 (Scheme 1).26 4-
Methylthiouridine-5′-monophosphate (42) was obtained by the treatment of 41 with 0.25 M
NaOH in methanol for 2 h at room temperature followed by reacting with an excess of
iodomethane at room temperature (Scheme 2).27 All synthesized and commercially available
nucleoside 5′-monophosphate analogues were passed through cation-exchange resin and
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neutralized with tributylamine. The salt form was changed to a tributylammonium salt to
allow the subsequent reaction to proceed in an anhydrous organic solvent. The nucleoside
5′-monophosphate was activated with 1,1′-carbonyldiimidazole in DMF for 6 h at room
temperature. After the reaction was quenched and the intermediate containing a 2′-cyclic
carbonyl group was hydrolyzed with methanol and triethylamine, the activated intermediate
was directly condensed with a glucose 1-monophosphate tributylammonium salt in DMF to
afford the corresponding nucleoside-5′-diphosphoglucose derivative (5, 6, 8 – 14, 16, 19,
22, 24).28,29 Several intermediates, including inositol-1-monophosphate, fructose-1-
monophosphate and mannose-1-monophosphate, were condensed with uridine-5′-
monophosphoimidazolide to afford the compounds 25-27.
The monophosphorylation of the 2′-amino-2′-deoxyuridine 32 using the above method
provided only the undesired 3′-monophosphate derivative.27 As an alternate approach to
synthesize 2′-deoxy-2′-aminouridine-5′-diphosphoglucose (7), the 2′-trifluoroacetylamino
derivative 33, formed after protection of the amino group in 32 with a trifluoroacetyl group,
was phosphorylated to give 38. However, the protecting group of 3 8 was removed during
the reaction to activate the phosphate with 1,1′-carbonyldiimidazole, and this reagent
formed a side product containing a cyclic carbonyl group between the 2′-amino and 3′-
oxygen. This intermediate was the precursor of compound 8, and it was necessary to prepare
compound 7 by another route, i.e. by reduction of the 2′-deoxy-2′-azidouridine-5′-
diphosphoglucose (6) with H2 and Pd/C.
1,1′-Carbonyldiimidazole activated not only the 5′-phosphate but also partially activated the
2′-hydroxy group of the intermediate 3′-deoxyuridine-5′-monophosphate (39). The
activated 2′-(imidazole-1-carbonyl) group was transformed to a methylcarbonate group
when it was exposed to MeOH. After these two transient intermediates were reacted with
glucose 1-monophosphate, compounds 9 and 10 were readily separated. When compound 36
was treated with 1,1′-carbonyldiimidazole, a cyclic 3′,5′-monophosphate imidazolide was
produced instead of the desired 5′-monophosphate imidazolide. Alternatively, compound 15
could be prepared from nucleoside 5′-phosphoromorpholidate using morpholine and DCC30
followed by the same method of condensing with glucose 1-monophosphate (Scheme 1).
Scheme 3 shows the synthesis of a sterically constrained analogue of 2′-deoxy-UDPG, the
(S)-methanocarba analogue 12. This analogue was prepared in an attempt to define the
preferred conformation of the ribose moiety in the receptor binding site. The corresponding
2′-hydroxy analogue, which perhaps would be more definitive, was not included in this
study.
To test the ability to combine the potency enhancing 2-thio modification with a substituted
hexose moiety, 2-thio-UDP-glucuronic acid 28, analogue was prepared. The method used
was an adaptation of a one-step selective enzymatic oxidation starting from the
corresponding glucose derivative 15, and the product was purified using HPLC.41
Quantification of Pharmacological Activity
Activation of phospholipase C was quantified in COS-7 cells transiently expressing the
human P2Y14 receptor and an engineered G protein, Gα-q/i protein (Gαqi5) that allows
coupling of Gi-coupled receptors to activation of phospholipase C.35 Thus, inositol lipid
hydrolysis33,34 served as a measure of agonist activity at the Gi-coupled P2Y14 receptor.
The high potency of analogues 2 and 3 suggested a flexibility of structural modification at
the glucose 4 and 6 positions. The 12-fold lower potency of 4a in comparison to 1 suggested
a limited tolerance for steric bulk at the glucose 2 position. Most of the novel UDPG
analogues modified on the uracil or ribose moieties were inactive. Thus, the SAR of the
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P2Y14 receptor is among the most restrictive of all of the P2Y receptors. For example, at the
P2Y6 receptor, most modifications of the uracil or ribose moieties reduced, but did not
entirely abolish activity. At the P2Y2/P2Y4 receptors, some of the same ribose modifications
introduced here (e.g. 2′-amino, 2′-azido) enhanced potency or selectivity.36 Analogues with
purine or pyrimidine base substitutions 19 – 21 and the dinucleotide U[5′]p2[5′]U 29a were
inactive at the P2Y14 receptor. Also, UMP, UDP, UTP, and U[5′]p4[5′]U failed to activate
the P2Y14 receptor (data not shown).
The SAR of the uracil moiety indicated that substitution of this entity was somewhat more
permissive than that of the ribose moiety. Among the novel analogues prepared, a 2-
thiouracil analogue 15 had a 7-fold higher potency (EC50 49 ± 2 nM) than that of UDPG
(Figure 1). A 4-thio analogue (13) was equipotent to UDPG, but its S-methylation (14) was
not tolerated for receptor activation. Also, three modifications at the 5 position of the uracil
moiety (16 – 18) resulted in inactivity.
Based on the potency of compounds 2 – 4 and on the modeling results (see below)
indicating as predominance of hydrophilic, H-bonding residues in the region of the hexose
moiety, we proposed that the glucose moiety of UDPG should be amenable to extensive
structural modification. Consequently, we synthesized UDP-fructose, UDP-mannose, and
UDP-inositol and tested these derivatives as agonists of the P2Y14 receptor. Indeed, such
variation of the glucose moiety of UDPG in the form of inositol 25, fructose 26, and
mannose 27 preserved the agonist potency at the P2Y14 receptor.
UDP-galactose 2, UDP-glucuronic acid 3, and UDP-N-acetylglucosamine 4a also were
agonists with potencies similar to that of UDP-glucose 1 at the P2Y14 receptor. The
maximal effect observed with 2, 3, and 4a was somewhat variable. Maximal effects identical
to that of UDP-glucose were observed in some experiments, whereas the maximal effects
observed with these three molecules were somewhat less than that of UDP-glucose in other
experiments. 2-Thio-UDP-glucuronic acid 28 acted as an agonist at the P2Y14 receptor and
was equipotent to compounds 1 and 3. Thus, the favorable 2-thio modification preserved but
did not enhance the potency of a hexose sugar-modified analogue.
Molecular Modeling
We recently reported a rhodopsin-based homology model of the human P2Y14 receptor
inserted into a phospholipid bilayer and refined by molecular dynamics (MD) simulation.31
The model was utilized to study the binding mode of UDPG at the P2Y14 receptor. Ligand
docking modes were based on automatic molecular docking protocols combined with the
Monte Carlo Multiple Minimum calculations. Despite being based on the ground-state of
rhodopsin, the model seems to be applicable to study ligand-receptor interactions for
agonists. For example, similar approaches to study the interactions of agonists with P2Y1
and P2Y6 receptors were recently reported24,37 The diphosphate moiety was found to
interact with only one cationic residue in the P2Y14 receptor, namely Lys171 of EL2, while
in other P2Y receptor subtypes three positively charged residues interact with the phosphate
chain. It should be noted that in nature the phosphate groups of UDPG could be also
coordinated by a metal cation. The model of the P2Y1 receptor complex with UTP-Mg2+
was recently reported by Major et al.38 The distal hexose moiety appeared to be H-bonded
by other conserved cationic residues, namely Arg253 (6.55) and Lys277 (7.35). To facilitate
the comparison among receptors, throughout this paper we use the GPCR residue indexing
system, as explained in detail elsewhere.32 To refine the binding mode of UDPG, especially
the binding mode of the hexose ring, the Monte Carlo Multiple Minimum (MCMM)
calculations were continued as described in the Methods section. The results of MCMM
calculations suggested that two conformations of the hexose ring are possible at the receptor
Ko et al. Page 4










binding site (Figure 2). However, values of total energy of the entire ligand-receptor
complex calculated for both models demonstrated that conformation A is more favorable.
This is in a good agreement with the hexose conformation in X-ray data published for
complexes of UDPG with various proteins.39 On the other hand, conformation B also seems
to be possible due to the interactions between Lys277 (7.35) and hydroxyl groups of the
hexose ring. These interactions can lock the hexose ring in its otherwise less favorable
conformation.
The UDPG binding mode A was proved by independently performed automatic docking of
the ligand with the Glide program of MacroModel.40 As mentioned in the Methods section,
a box with a side of 46 Å around the centroid of three conserved cationic residues was used
for the docking study covering more than half of the entire receptor (Figure 3). The binding
mode of UDPG obtained after the Glide-aided molecular docking was very similar to the
binding mode of UDPG obtained after MCMM calculations.
It was observed in the docking model obtained for UDPG (Figure 4) that, in the case of
conformation A, Lys171 (EL2) can form an electrostatic interaction with the β-phosphate
group and an additional hydrogen bond with the hydroxyl group at the 5 position of the
hexose ring. Also this hydroxyl group of UDPG can interact with the backbone oxygen atom
of a conserved Cys172 (EL2). The β-phosphate group formed a H-bond with the hydroxyl
group of Thr280 (7.38), while Ser284 (7.42) appeared in proximity to the α-phosphate
group of UDPG. K277 (7.35) interacted with hydroxyl groups at the hexose 2 and 3
positions, while Arg253 (6.55) was found near the hydroxyl group at position 3. The
glutamate residue Glu174 (EL2) can interact with hydroxyl groups at the 3 and 4 positions
of the hexose ring. The second glutamate residue Glu166 (EL2) appeared near hydroxyl
groups at the 2 and 3 positions and in proximity to Lys277 (7.35). Similarly, hexose binding
regions in protein crystallographic structures typically contain charged amino acid side
chains, which H-bond to the hydroxyl groups.39
The hydroxyl groups of the ribose moiety of UDPG were found to be H-bonded with two
asparagine residues. In particular, it was observed that the 2′-hydroxyl group can interact
with the sidechain amino group of Asn104 (3.35) and the sidechain C=O group of Asn287
(7.45). The 3′-hydrogen group of UDPG seemed to be H-bonded with the sidechain amino
group of Asn287 (7.45). These results are in a good agreement with the experimental values
of EC50 measured for the ribose-modified UDPG derivatives suggesting the importance of
both 2′- and 3′-hydroxyl groups.
Similar to our previous model,31 the ribose ring oxygen atom was not involved in hydrogen
bonding with the receptor. This observation makes it possible to propose that replacement of
this oxygen atom of UDPG by a carbon atom will not decrease the potency of a ligand.
Several examples of such modifications of the ribose ring were already published for other
subtypes of P2Y receptors.
As shown in Table 1, replacement of the oxygen atom at the uracil 2 position of UDPG by a
sulfur atom increases agonist potency. This finding is in good agreement with the receptor
docking models obtained for UDPG and 2-thio-UDPG 15 (Figure 4), in which there is a
mainly hydrophobic pocket surrounding the 2 position of the uracil ring. The oxygen atom at
the 2 position of UDPG was not involved in H-bonding with the receptor, implying that this
oxygen is not critical for ligand recognition. The more hydrophobic sulfur atom of larger
radius at the 2 position of 15 would be expected to favorably occupy more free space inside
this pocket and result in improved potency of the ligand. The sulfur atom at the 2 position of
the uracil ring occupied a space between several residues, namely Val32 (1.42), Met70
(2.53), Ala285 (7.43), and Val288 (7.46).
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The binding modes of several UDP derivatives with various sugar moieties were examined
with molecular docking studies. In particular, binding modes of UDP-mannose 27 and UDP-
inositol 25 were studied. In general, the position and conformation of these two ligands were
found to be very similar to UDPG. In the case of 27, the 2-OH group was located closer to
Glu166 than to Lys277 (7.35), which formed a H-bond with the 3-OH group. Also, hydroxyl
groups at the 3 and 4 positions of 27 formed H-bonds with Glu174 (EL2). The hydroxyl
group at the 5 position can form a H-bond with Lys171 (EL2), while the oxygen atom of the
mannose ring of 27 was not involved in H-bonding with the receptor.
The molecular model of the P2Y14 receptor with UDP-inositol 25 obtained after MCMM
calculations indicated that similar to UDPG and 27, the ligand 25 can interact with Lys277
(7.35) and Glu174 (EL2) due to H-bonding between these residues and the hydroxyl groups
at the 3 and 4 positions of the inositol moiety. In addition, the 3-OH group of the inositol
moiety can interact with Arg253 (6.55). In contrast, Glu166 (EL2) appeared far from the
hydroxyl groups of 25 and did not form H-bonds with the ligand. The hydroxyl group at the
6 position of the inositol ring was found near Lys171 (EL2). We propose that introduction of
negatively charged groups at 2, 3, and 6 positions of the inositol ring could provide more
favorable interactions with cationic residues.
Among UDP derivatives is a five-membered sugar ring derivative, UDP-fructose 26. The
docking complex of 26 in the P2Y14 receptor indicated that the ligand can form several H-
bonds with the P2Y14 receptor (Figure 5). In particular, similar to UDPG, the oxygen atom
of the hydroxyl group at the 5 position of 26 can be H-bonded to Lys171 (EL2). In addition,
Lys171 can interact with the ring oxygen atom of the fructose moiety. The H-bonds between
the ligand and Glu166 (EL2) were not observed in the model obtained after MCMM
calculations. However, the hydroxyl group at the 4 position was H-bonded to Glu174 (EL2)
and could interact with the backbone oxygen atom of Cys172 (EL2). The 3-hydroxyl group
of the fructose moiety was also found to be H-bonded with Glu174 (EL2) and with Lys277.
The results of molecular docking performed for ligands containing various other sugar
moieties 25 – 27 indicated that all these structures display similar binding modes at the
P2Y14 receptor. In general, the sugar moieties of these ligands were involved in similar
interactions with the receptor as UDPG. For this reason, compounds 25 – 27 were proposed
as potential agonists of the P2Y14 receptor and subsequently synthesized and tested
biologically (see above).
Conclusions
We have identified various modifications that deselect for this receptor subtype in relation to
other uracil nucleotide-responsive receptors and one modification (i.e. 2-thio) that provides
higher potency at the P2Y14 receptor. The 4-thio analogue of UDPG was equipotent to the
parent nucleotide. Most other modifications of the uracil or ribose moieties led to inactivity.
Thus, the P2Y14 receptor is among the least permissive P2Y receptors with respect to SAR.
The molecular modeling studies allowed us to propose that the glucose moiety can be
replaced by various six-membered or five-membered sugar rings. This prediction was tested
experimentally and it was shown that variation of the glucose moiety of UDPG in the form
of inositol, fructose, and mannose preserved the potency. In the models all these sugar
moieties were able to interact with various hydrophilic and H-bonding side chains located in
the vicinity. Therefore, the hexose moiety provides a fertile region for chemical
modification of P2Y14 receptor agonists.
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2-Thiouridine (30) was purchased from Berry & Associates, Inc. (Dexter, MI). 2′-Azido-2′-
deoxyuridine (31) and 2′-amino-2′-deoxyuridine (32) were purchased from CMS Chemicals
Ltd. (Oxfordshire, UK). 3′-Deoxyuridine (34) was purchased from T.R.C., Inc. (North
York, Ontario, Canada). 2′-Ara-fluoro-2′-deoxyuridine (35) was purchased from R.I.
Chemical, Inc. (Orange, CA). 5-Azidouridine diphosphoglucose (17) and 5-aminouridine
diphosphoglucose (18) were purchased from A.L.T., Inc. (Lexington, KY). Compounds 1 –
4, 20, 21, 23, and all reagents and solvents were purchased from Sigma-Aldrich (St. Louis,
MO). Compounds 5, 19, 22, 29a, and 29b were synthesized as reported.28
1H NMR spectra were obtained with a Varian Gemini 300 spectrometer using D2O as a
solvent. The chemical shifts are expressed as relative ppm from HOD (4.78 ppm). 31P NMR
spectra were recorded at room temperature by use of Varian XL 300 spectrometer (121.42
MHz); orthophosphoric acid (85%) was used as an external standard. Purity of compounds
was checked using a Hewlett–Packard 1100 HPLC equipped with a Luna 5 µ RP-C18(2)
analytical column (250 × 4.6 mm; Phenomenex, Torrance, CA). System A: linear gradient
solvent system: 5 mM TBAP (tetrabutylammonium dihydrogenphosphate)-CH3CN from
80:20 to 40:60 in 20 min, then isocratic for 2 min; the flow rate was 1 mL/min. System B:
linear gradient solvent system: 10 mM TEAA (triethylammonium acetate)-CH3CN from
100:0 to 85:15 in 20 min, then isocratic for 2 min; the flow rate was 1 mL/min. Purity of
compounds 6 – 16 and 24 – 27 in system B was checked using a Zorbax Eclipse 5 µm XDB-
C18 analytical column (250 × 4.6 mm; Agilent Technologies Inc, Palo Alto, CA). Peaks
were detected by UV absorption with a diode array detector. All derivatives tested for
biological activity showed >98% purity in the HPLC systems.
High-resolution mass measurements were performed on Micromass/Waters LCT Premier
Electrospray Time of Flight (TOF) mass spectometer coupled with a Waters HPLC system.
Purification of the nucleotide analogues for biological testing was carried out on
(diethylamino)ethyl (DEAE)-A25 Sephadex columns as described below. Compounds 6, 7,
9, 10, 12, 16 and 25 – 27 were additionally purified by HPLC using system C. System C:
gradient solvent system: 10 mM TEAA-CH3CN from 100:0 to 90:10 in 30 min, then
isocratic for 2 min; the flow rate was 2 mL/min with a Luna 5 µ RP-C18(2) semi-preparative
column (250 × 10.0 mm; Phenomenex, Torrance, CA).
General Procedure for the Preparation of Nucleoside 5′-monophosphates. Procedure A
A solution of the corresponding nucleoside (0.04–0.19 mmol) and Proton Sponge (1.5
equiv) in trimethyl phosphate (2 mL) was stirred for 10 min at 0 °C. Then phosphorous
oxychloride (2 equiv) was added drop wise, and the reaction mixture was stirred for 2 hours
at 0 °C. 0.2 M triethylammonium bicarbonate solution (2 mL) was added to the reaction
mixture, and the clear solution was stirred at room temperature for 1 h. The latter was
lyophilized overnight. The residue was purified by ion-exchange column chromatography
using a Sephadex-DEAE A-25 resin with a linear gradient (0.01–0.5 M) of 0.5 M
ammonium bicarbonate as the mobile phase. The portions of desired compounds were
collected, frozen and lyophilized to give the corresponding nucleoside 5′-monophosphates
as the ammonium salts.
General Procedure for the Preparation of Nucleoside 5′-diphosphoglucose Procedure B
An ammonium salt or sodium salt of the nucleoside 5′-monophosphate (0.01–0.02 mmol)
was treated with ion-exchange resin (DOWEX® 50WX2-200 (H)) followed by
neutralization with tributylamine. The mixture was evaporated and lyophilized to afford the
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nucleoside 5′-monophosphate tributylamine salt. To a solution of the dried corresponding
nucleoside 5′-monophosphates tributylamine salt in DMF (1.5–2.0 mL) was added 1,1′-
carbonyldiimidazole (3 equiv). The reaction mixture was stirred at room temperature for 6 h.
Then 5% triethylamine solution in 1/1 water/methanol (2 mL) was added and stirring was
continued at room temperature for additional 2 h. After removal of the solvent, the residue
was dried in high vacuum and dissolved in DMF (1 mL). Glucose-1-monophosphate
tributylammonium salt (1.5 equiv, inositol-1-monophsphate for compound 25, fructose-1-
monophosphate for compound 26, and mannose-1-monophosphate for compound 27 were
used.) was added to a solution of the nucleotide imidazolide in DMF. The reaction mixture
was stirred at room temperature for 2 days. After removal of the solvent, the residue was
purified by ion-exchange column chromatography using a Sephadex-DEAE A-25 resin with
a linear gradient (0.01–0.5 M) of 0.5 M ammonium bicarbonate as the mobile phase. The
portion of desired compounds were collected, frozen and lyophilized to give the
corresponding nucleoside 5′-diphosphoglucoses as the ammonium salts. Some of the
products were additionally purified by HPLC using system C.
((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methyl phosphate, Ammonium salt (36). Procedure A—
Compound 36 (8 mg, 35%) was obtained from 30 (15 mg, 0.06 mmol). 1H NMR (D2O) δ
8.21 (d, J=8.1 Hz, 1H), 6.64 (d, J=2.7 Hz, 1H), 6.22 (d, J=8.1 Hz, 1H), 4.23 (dd, J=4.5, 3.0
Hz, 1H), 4.31 (br d, J=3.0 Hz, 1H), 4.26 (dd, J=12.3, 3.9 Hz, 1H), 4.11 (dd, J=12.0, 5.0 Hz ,
1H); 31P NMR (D2O) δ 0.81 (s); HRMS m/z found 339.0056 (M – H+)−. C9H12N2O8P2S
requires 339.0052.
((2R,3S,4R,5R)-4-azido-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-
hydroxytetrahydrofuran-2-yl)methyl phosphate, Ammonium salt (37).
Procedure A—Compound 37 (7 mg, 41%) was obtained from 31 (12 mg, 0.045
mmol). 1H NMR (D2O) δ 7.91 (d, J=8.1 Hz, 1H), 5.98 (d, J=5.1 Hz, 1H), 5.91 (d, J=8.1 Hz,
1H), 4.52 (t, J=5.4 Hz, 1H) 4.32 (t, J=5.4 Hz, 1H), 4.23 (m, 1H), 4.18 (ddd, J=12.0, 4.5, 2.7
Hz, 1H), 4.08 (ddd, J=12.0, 5.1, 2.7 Hz, 1H); 31P NMR (D2O) δ −3.52 (s); HRMS m/z
found 348.0366 (M – H+)−. C9H11N5O8P requires 348.0345.
((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxy-4-(2,2,2-
trifluoroacetamido)tetrahydrofuran-2-yl)methyl phosphate, Ammonium salt
(38). Procedure A—Compound 38 (3.2 mg, 45%) was obtained from 33 (5.8 mg, 0.017
mmol). 1H NMR (D2O) δ 8.09 (dd, J=8.4, 1.8 Hz, 1H), 6.05 (d, J=8.1 Hz, 1H), 6.00 (dd,
J=7.8, 1.5 Hz, 1H), 4.41 (m, 1H), 4.31 (m, 1H), 3.96 (m, 2H), 3.80 (m, 1H); 31P NMR
(D2O) δ 3.85 (s); HRMS m/z found 418.0251 (M – H+)−. C11H12N3O9F3P1 requires
418.0263.
((2S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
hydroxytetrahydrofuran-2-yl)methyl phosphate, Ammonium salt (39).
Procedure A—Compound 39 (9.2 mg, 41%) was obtained from 34 (15 mg, 0.066
mmol). 1H NMR (D2O) δ 8.09 (d, J=8.1 Hz, 1H), 5.88 (d, J=7.8 Hz, 1H), 5.79 (d, J=1.2 Hz,
1H), 4.59 (m, 1H), 4.48 (m, 1H), 4.09 (ddd, J=11.7, 4.5, 2.7 Hz, 1H), 3.86 (ddd, J=11.7, 4.5,
4.5 Hz, 1H), 2.14 (ddd, J=14.1, 9.6, 5.7 Hz, 1H), 2.00 (ddd, J=13.8, 6.3, 2.7 Hz, 1H); 31P
NMR (D2O) δ 2.35 (s); HRMS m/z found 307.0309 (M – H+)−. C9H12N2O8P requires
307.0331.
((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-
hydroxytetrahydrofuran-2-yl)methyl phosphate, Ammonium salt (40).
Procedure A—Compound 40 (9.5 mg, 33%) was obtained from 35 (20 mg, 0.08
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mmol). 1H NMR (D2O) δ 7.90 (dd, J=8.1, 1.2 Hz, 1H), 6.31 (dd, J=15.9, 4.2 Hz, 1H), 5.89
(dd, J=8.1, 1.2 Hz, 1H), 5.21 (d, J=51.5, 3.0 Hz, 1H), 4.52 (d, J=19.2, 4.2 Hz, 1H), 4.18 (m,
3H); 31P NMR (D2O) δ 4.75 (s); HRMS m/z found 325.0240 (M – H+)−. C9H11N2O8FP
requires 325.0237.
((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-(methylthio)-2-oxopyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methyl phosphate, Ammonium salt (42)—To a suspension
of 4-thiouridine 5′-monophosphate, 41 (sodium salt, 10 mg, 0.03 mmol) in MeOH/H2O (1.0
mL/0.5 mL) was added 0.25 M NaOH (0.5 mL). The reaction mixture was stirred at room
temperature for 2 h and then the solvent was removed under the high vacuum. The resulting
residue was dissolved in dry DMF (2.0 mL) and iodomethane (0.09 mL, 1.5 mmol) was
added. The reaction mixture was stirred at room temperature for 1 h, and an additional 0.09
mL of iodomethane was added. After 2 h, the solvent was removed under the reduced
pressure. The crude compound was purified by the same method in procedure A to give 42
(7 mg, 62%). 1H NMR (D2O) δ 8.40 (d, J=6.9 Hz, 1H), 6.78 (d, J=7.5 Hz, 1H), 5.97 (d,
J=2.4 Hz, 1H), 4.34-4.37 (m, 2H), 4.30 (m, 1H), 4.10-4.17 (m, 1H), 3.96-4.02 (m, 1H); 31P
NMR (D2O) δ 2.09 (s); HRMS m/z found 353.0238 (M – H+)−. C10H14N2O8SP requires
325.0209.
Diphosphoric acid 1-α-D-glucopyranosyl ester 2-((2"-deoxy-2"-azido)uridin-5"-
yl) ester, Triethylammonium salt (6). Procedure B—Compound 6 (2.5 mg, 63%)
was obtained from 37 (ammonium salt, 2 mg, 0.005 mmol). 1H NMR (D2O) δ 7.94 (d, J=8.1
Hz, 1H), 6.01 (d, J=5.4 Hz, 1H), 5.96 (d, J=7.8 Hz, 1H), 5.58 (dd, J=7.2, 3.6 Hz, 1H), 4.80
(m, 1H), 4.36 (t, J=5.4 Hz, 1H), 4.19-4.25 (m, 3H), 3.82-3.89 (m, 2H), 3.72-3.78 (m, 2H),
3.51 (dd, J=9.9, 3.0 Hz, 1H), 3.44 (t, J=9.6 Hz, 1H); 31P NMR (D2O) δ −10.89 (d, J=20.8
Hz), −12.47 (d, J=20.8 Hz); HRMS m/z found 590.0531 (M – H+)−. C15H22N5O16P2
requires 590.0537; HPLC (System A) 13.7 min (98%), (System B) 7.2 min (98%).
Diphosphoric acid 1-α-D-glucopyranosyl ester 2-((2"-deoxy-2"-
amino)uridin-5"-yl) ester, Triethylammonium salt (7)—H2 at atmospheric pressure
was applied to a mixture of 6 (1.5 mg, 0.002 mmol) and Pd/C 10% (0.3 mg) in MeOH (0.5
mL) for 2 h at room temperature. The reaction mixture was filtered and the filtrate was
evaporated under the reduced pressure. The residue was purified by HPLC using system C
to afford 7 (1.0 mg, 69%). 1H NMR (D2O) δ 7.96 (d, J=7.8 Hz, 1H), 6.02 (d, J=7.8 Hz, 1H),
5.98 (d, J=8.1 Hz, 1H), 5.62 (dd, J=8.1, 3.6 Hz, 1H), 4.38 (m, 1H), 4.33 (m, 1H), 4.20 (m,
2H), 3.77-3.91 (m, 4H), 3.46-3.64 (m, 3H); 31P NMR (D2O) δ −10.83 (d, J=20.8 Hz),
−12.49 (d, J=20.8 Hz); HRMS m/z found 564.0600 (M – H+)−. C15H24N3O16P2 requires
564.0632; HPLC (System A) 5.7 min (98%), (System B) 5.4 min (98%).
Diphosphoric acid 1-α-D-glucopyranosyl ester 2-((2"-deoxy-2"-
aminocarbonyl-3"-O)uridin-5"-yl) ester, Ammonium salts (8). Procedure B—
Compound 8 (2.0 mg, 48%) was obtained from 38 (ammonium salt, 3.0 mg, 0.007
mmol). 1H NMR (D2O) δ 7.84 (d, J=8.4 Hz, 1H), 5.91 (m, 2H), 5.59 (dd, J=7.5, 3.6 Hz,
1H), 5.40 (dd, J=8.4, 3.3 Hz, 1H), 4.67-4.75 (m, 2H), 4.30 (m, 2H), 3.75-3.92 (m, 4H),
3.43-3.55 (m, 2H); 31P NMR (D2O) δ −11.25 (br s), −12.52 (br s); HRMS m/z found
590.0449 (M – H+)−. C16H22N3O17P2 requires 590.0424; HPLC (System A) 11.7 min
(98%), (System B) 5.5 min (98%).
Diphosphoric acid 1-α-D-glucopyranosyl ester 2-((3"-deoxy)uridin-5"-yl) ester,
Triethylammonium salt (9) and Diphosphoric acid 1-α-D-glucopyranosyl ester
2-((2",3"-dideoxy-2"-acetyloxy)uridin-5"-yl) ester, Triethylammonium salt (10).
Procedure B—Compounds 9 (1.3 mg, 7%) and 10 (3.4 mg, 16%) were obtained from 39
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(ammonium salts, each: 9 mg, 0.026 mmol). Compound 9 1H NMR (D2O) δ 8.02 (d, J=8.1
Hz, 1H), 5.95 (d, J=8.1 Hz, 1H), 5.85 (d, J=2.1 Hz, 1H), 5.62 (dd, J=7.2, 3.3 Hz, 1H), 4.71
(m, 1H), 4.54 (m, 1H), 4.34 (m, 1H), 4.15 (m, 1H), 3.77-3.93 (m, 4H), 3.44-3.57 (m, 2H),
2.07-2.24 (m, 2H); 31P NMR (D2O) δ −10.66 (d, J=21.5 Hz), −12.48 (d, J=20.8 Hz); HRMS
m/z found 549.0543 (M – H+)−. C15H23N2O16P2 requires 549.0523; HPLC (System A) 12.9
min (98%), (System B) 8.5 min (98%). Compound 10 1H NMR (D2O) δ 7.96 (d, J=8.1 Hz,
1H), 6.02 (d, J=1.5 Hz, 1H), 5.96 (d, J=7.8 Hz, 1H), 5.61 (dd, J=7.2, 3.6 Hz, 1H), 5.37 (m,
1H), 4.65 (m, 1H), 4.35 (ddd, J=11.7, 5.1, 2.4 Hz, 1H), 4.14 (ddd, J=11.7, 6.3, 4.2 Hz, 1H),
3.92 (m, 1H), 3.84 (s, 3H), 3.76-3.86 (m, 3H), 3.54 (dt, J=9.9, 3.3 Hz, 1H), 3.47 (t, J=9.3
Hz, 1H), 2.44 (m, 1H), 2.31 (ddd, J=14.1, 6.0, 2.1 Hz, 1H); 31P NMR (D2O) δ −10.72 (d,
J=20.8 Hz), −12.47 (d, J=20.8 Hz); HRMS m/z found 607.0568 (M – H+)−. C17H25N2O18P2
requires 607.0578; HPLC (System A) 13.1 min (98%), (System B) 8.0 min (98%).
Diphosphoric acid 1-α-D-glucopyranosyl ester 2-((2'-fluoro-2"-
deoxyara)uridin-5"-yl)ester, Ammonium salts (11). Procedure B—Compound 11
(ammonium salt, 2.4 mg, 24%) was obtained from 40 (ammonium salt, 6 mg, 0.017
mmol). 1H NMR (D2O) δ 7.92 (dd, J=8.1, 1.2 Hz, 1H), 6.33 (dd, J=15.9, 3.9 Hz, 1H), 5.94
(d, J=8.4 Hz, 1H), 5.61 (dd, J=7.2, 3.6 Hz, 1H), 5.23 (dd, J=51.3, 4.2 Hz, 1H), 4.57 (dd,
J=18.9, 3.3 Hz, 1H), 4.25 (m, 3H), 3.76-3.92 (m, 4H), 3.44-3.56 (m, 2H); 31P NMR (D2O) δ
−10.73 (d, J=20.8 Hz), −12.45 (d, J=20.8 Hz); HRMS m/z found 567.0427 (M – H+)−.
C15H22N2O16FP2 requires 567.0429; HPLC (System A) 11.7 min (98%), (System B) 8.4
min (98%).
Diphosphoric acid 1-α-D-glucopyranosyl ester 2-(((S)-methanocarba-2"-
deoxy)uridin-5"-yl)ester, Triethylammonium salt (12). Procedure B—Compound
12 (1.4 mg, 59%) was obtained from 4524 (ammonium salt, 1.1mg, 0.003 mmol). 1H NMR
(D2O) δ 7.81 (d, J=8.1 Hz, 1H), 5.80 (d, J=7.8 Hz, 1H), 5.59 (dd, J=6.9, 3.3 Hz, 1H), 4.37
(d, J=6.6 Hz, 1H), 4.09 (m, 2H), 3.74-3.87 (m, 4H), 3.42-3.53 (m, 2H), 2.40 (m, 1H), 2.19
(m, 2H), 1.86 (m, 1H), 1.63 (m, 1H), 1.37 (m, 1H); 31P NMR (D2O) δ −10.48 (d, J=20.8
Hz), −12.53 (d, J=20.8 Hz); HRMS m/z found 559.0735 (M – H+)−. C17H25N2O15P2
requires 559.0730; HPLC (System A) 11.6 min (98%), (System B) 7.9 min (98%).
Diphosphoric acid 1-α-D-glucopyranosyl ester 2-((4'-thio)uridin-5"-yl)ester,
Ammonium salts (13). Procedure B—Compound 13 (1.9 mg, 18 %) was obtained
from 41 (12 mg, 0.017 mmol). 1H NMR (D2O) δ 7.86 (d, J=7.8 Hz, 1H), 6.68 (d, J=7.5 Hz,
1H), 5.96 (d, J=3.6 Hz, 1H), 5.62 (dd, J=7.5, 3.6 Hz, 1H), 4.23-4.39 (m, 5H), 3.83-3.90 (m,
2H), 3.76-3.84 (m, 2H), 3.54 (dt, J=9.0, 3.0 Hz, 1H), 3.48 (dd, J=9.9, 9.3 Hz, 1H); 31P NMR
(D2O) δ −10.33 (d, J=20.8 Hz), −12.46 (d, J=20.8 Hz); HRMS m/z found 581.0249 (M –
H+)−. C15H23N2O16P2S requires 581.0224; HPLC (System A) 13.7 min (98%), (System B)
6.6 min (98%).
Diphosphoric acid 1-α-D-glucopyranosyl ester 2-((4'-methylthio)uridin-5"-
yl)ester, Ammonium salts (14). Procedure B—Compound 14 (5.1 mg, 40 %) was
obtained from 42 (ammonium salt, 6.2 mg, 0.016 mmol). 1H NMR (D2O) δ 8.20 (d, J=7.5
Hz, 1H), 6.76 (d, J=7.2 Hz, 1H), 5.94 (d, J=2.4 Hz, 1H), 5.59 (dd, J=6.9, 3.0 Hz, 1H),
4.18-4.35 (m, 5H), 3.73-3.90 (m, 4H), 3.20-3.53 (m, 2H), 2.53 (s, 3H); 31P NMR (D2O) δ
−10.80 (d, J=20.8 Hz), −12.46 (d, J=20.8 Hz); HRMS m/z found 595.0415 (M – H+)−.
C16H25N2O16P2S requires 595.0400; HPLC (System A) 14.2 min (98%), (System B) 8.0
min (98%).
Diphosphoric acid 1-α-D-glucopyranosyl ester 2-((2'-thio)uridin-5"-yl)ester,
Ammonium salts (15)—To a suspension of 36 (tributylammonium salt, 8 mg, 0.01
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mmol) in t-BuOH/H2O (0.5 mL/0.5 mL) were added morpholine (0.006 mL, 0.06 mmol)
and DCC (14 mg, 0.06 mmol). The reaction mixture was heated to reflux for 4 h and cooled
to room temperature. After removal of solvent, the reaction was diluted with H2O and
washed with diethyl ether twice. The aqueous layer was concentrated and passed through
H2O and ion-exchange resin (DOWEX® 50WX2-200 (H)) followed by treatment with
tributylamine. After removal of all solvents, the residue was dried in high vacuum and
dissolved in DMF (1 mL). Glucose-1-monophosphate tributylammonium salt was added to a
solution of the nucleotide morpholidate in DMF. The reaction mixture was stirred for 2 days
followed by the same purification procedure B to give 15 (5 mg, 77%). 1H NMR (D2O) δ
8.15 (d, J=8.4 Hz, 1H), 6.68 (d, J=3.0 Hz, 1H), 6.26 (d, J=8.1 Hz, 1H), 5.61 (dd, J=6.9, 3.3
Hz, 1H), 4.20-4.45 (m, 5H), 3.70-3.95 (m, 4H), 3.54 (dt, J=9.0, 2.7 Hz, 1H), 3.47 (t, J=9.3
Hz, 1H); 31P NMR (D2O) δ −10.23 (d, J=20.8 Hz), −11.83 (d, J=20.8 Hz); HRMS m/z
found 581.0248 (M – H+)−. C15H23N2O16P2S requires 581.0244; HPLC (System A) 12.6
min (98%), (System B) 5.0 min (98%).
Diphosphoric acid 1-α-D-glucopyranosyl ester 2-((5'-iodo)uridin-5"-yl)ester,
Triethylammonium salt (16). Procedure B—Compound 16 (1.4 mg, 11%) was
obtained from 43 (sodium salt, 7 mg, 0.014 mmol) 1H NMR (D2O) δ 8.27 (s, 1H), 5.95 (d,
J=4.8 Hz, 1H), 5.63 (dd, J=6.9, 4.5 Hz, 1H), 4.23-4.42 (m, 5H), 3.77-4.01 (m, 4H), 3.54 (dt,
J=9.0, 3.0 Hz, 1H), 3.47 (t, J=9.6 Hz, 1H); 31P NMR (D2O) δ −10.40 (d, J=20.8 Hz), −11.87
(d, J=20.8 Hz); HRMS m/z found 690.9444 (M – H+)−. C15H22N2O17IP2 requires 690.9439;
HPLC (System A) 12.8 min (98%), (System B) 6.9 min (98%).
Diphosphoric acid 1-α-D-glucopyranosyl ester 2-((2"-deoxy-5'-flouro)uridin-5"-
yl)ester, Ammonium salts (24). Procedure B—Compound 24 (1.8 mg, 21%) was
obtained from 44 (tributylammonium salt, 10 mg, 0.014 mmol).1H NMR (D2O) δ 8.04 (d,
J=5.7 Hz, 1H), 6.30 (t, J=6.9 Hz, 1H), 5.59 (dd, J=7.5, 3.2 Hz, 1H), 4.18 (m, 2H), 3.74-3.91
(m, 4H), 3.42-3.53 (m, 2H), 3.10-3.21 (m, 2H), 2.34-2.38 (m, 2H); 31P NMR (D2O) δ
−10.89 (d, J=20.8 Hz), −12.51 (d, J=20.8 Hz); HRMS m/z found 386.9995 (M – H+)−.
C9H13N2O11P2 requires 386.9995; HPLC (System A) 14.5 min (98%), (System B) 4.8 min
(98%).
UDP-inositol, Triethylammonium salt (25). Procedure B—Compound 25 (3.2 mg,
30%) was obtained from uridine-5′-monophosphate (tributylammonium salt, 10 mg, 0.014
mmol).1H NMR (D2O) δ 7.97 (d, J=7.8 Hz, 1H), 5.99 (m, 2H), 4.72 (m, 1H), 4.40 (m, 2H),
4.31 (m, 1H), 4.26 (m, 2H), 3.74 (t, J=9.9 Hz, 2H), 3.56 (m, 2H), 3.30 (t, J=9.3 Hz, 1H); 31P
NMR (D2O) δ −9.95 (d, J=21.4 Hz), −10.56 (d, J=21.4 Hz); HRMS m/z found 565.0463 (M
– H+)−. C15H23N2O17P2 requires 565.0472; HPLC (System A) 12.3 min (98%), (System B)
9.2 min (98%).
UDP-fructose, Triethylammonium salt (26). Procedure—Compound 26 (4.0 mg,
37%) was obtained from uridine-5′-monophosphate (tributylammonium salt, 10 mg, 0.014
mmol). 1H NMR (D2O) δ 7.98 (d, J=8.1 Hz, 1H), 6.00 (m, 2H), 4.40 (m, 2H), 4.31 (m, 1H),
4.26 (m, 2H), 4.04-4.11 (m, 2H), 3.94-4.01 (m, 2H), 3.91 (m, 1H), 3.85 (m, 1H), 3.72 (m,
1H); 31P NMR (D2O) δ −10.82 (d, J=4.2 Hz), −10.96 (s); HRMS m/z found 565.0468 (M –
H+)−. C15H23N2O17P2 requires 565.0472; HPLC (System A) 12.4 min (98%), (System B)
8.7 min (98%).
UDP-mannose, Triethylammonium salt (27). Procedure B—Compound 27 (2.8
mg, 26%) was obtained from uridine-5′-monophosphate (tributylammonium salt, 10 mg,
0.014 mmol). 1H NMR (D2O) δ 7.99 (d, J=8.4 Hz, 1H), 6.00 (m, 2H), 5.53 (dd, J=7.2, 2.3
Hz, 1H), 4.40 (m, 2H), 4.31 (m, 1H), 4.25 (m, 2H), 4.07 (m, 1H), 3.67-3.97 (m, 5H); 31P
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NMR (D2O) δ −11.17 (d, J=20.8 Hz), −13.46 (d, J=20.9 Hz); HRMS m/z found 565.0471
(M – H+)−. C15H23N2O17P2 requires 565.0472; HPLC (System A) 12.5 min (98%), (System
B) 7.8 min (98%).
Diphosphoric acid 1-α-D-glucopyranosuronic acid 2-((2'-thio)uridin-5"-
yl)ester, Triethylammonium salts (28)—Compound 15 (ammonium salt, 0.7 mg, 0.001
mmol) was dissolved in 0.7 mL of stock solution (stock solution: Tris buffer (pH 7.4, 10
mL), NAD (17 mg, 0.026 mmol), sodium pyruvate (177 mg, 1.6 mmol), and lactate
dehydrogenase (67 U, EC 1.1.1.27, from rabbit muscle, Sigma). The pH of this solution was
adjusted to 8.7 with 0.05 NaOH). Uridine-5′-diphosphoglucose dehydrogenase (0.3 U,
Sigma, from bovine liver) was added to the mixture.41 The reaction was monitored by
HPLC (System A). After 20 h at room temperature, an additional 0.1 U of UDPG
dehydrogenase was added. After 5 h, the reaction mixture was lyophilized and purified by
HPLC (gradient solvent system: 10 mM TEAA-CH3CN from 100:0 to 97:3 in 40 min, then
isocratic for 5 min; the flow rate was 2 mL/min with a Luna 5 µ RP-C18(2) semi-preparative
column (250 × 10.0 mm; Phenomenex, Torrance, CA)). The portion of desired compound
was collected, frozen and lyophilized to give 28 (0.5 mg, 0.56 µmol, 56%, starting material
15 (0.3 mg, 0.38 µmol, 38%) was recovered). 1H NMR (D2O) δ 8.17 (d, J=8.1 Hz, 1H), 6.72
(d, J=3.3 Hz, 1H), 6.24 (d, J=7.5 Hz, 1H), 5.63 (dd, J=7.2, 3.0 Hz, 1H), 4.43(m, 1H), 4.33
(m, 2H), 4.24 (m, 1H), 4.10-4.16 (m, 2H), 3.78 (t, J=9.6 Hz, 1H), 3.57 (m, 1H), 3.51 (t,
J=9.6 Hz, 1H); 31P NMR (D2O) δ −10.81 (br s), −12.45 (br s); HRMS m/z found 595.0032
(M – H+)−. C15H21N2O17P2S requires 595.0036; HPLC (System A) 17.1 min (98%),
(System B) 12.4 min (98%).
Assay of P2Y14 receptor-stimulated PLC activity
COS-7 cells were transiently transfected with the human P2Y14 receptor and Gαqi5.35
Twenty-four hours after transfection, the inositol lipid pool of the cells was radiolabeled by
incubation in 200 µL of serum-free inositol-free Dulbecco's modified Eagle's medium,
containing 0.4 µCi of myo-[3H]inositol. No changes of medium were made subsequent to
the addition of [3H]inositol. Forty-eight hours after transfection, cells were challenged with
50 µL of the five-fold concentrated solution of receptor agonists in 200 mM N-(2-
hydroxyethyl)-piperazine-N′-2-ethanesulfonic acid, pH 7.3, containing 50 mM LiCl for 20
min at 37 °C. Incubations were terminated by aspiration of the drug-containing medium and
addition of 450 µL of ice-cold 50 mM formic acid. After 15 min at 4 °C, samples were
neutralized with 150 µL of 150 mM NH4OH. [3H]Inositol phosphates were isolated by ion
exchange chromatography on Dowex AG 1-X8 columns as previously described.34
Data Analysis
Agonist potencies (EC50 values) were obtained from concentration-response curves by non-
linear regression analysis using the GraphPad software package Prism (GraphPad, San
Diego, CA). All experiments were performed in triplicate assays and repeated at least three
times. The results are presented as mean ± SEM from multiple experiments or in the case of
concentration effect curves from a single experiment carried out with triplicate assays that
were representative of results from multiple experiments.
Molecular Modeling
Conformational Search—The recently reported complex of the P2Y14 receptor with
UDPG was utilized as a starting point for further calculations31. The conformational
analysis of the UDP-sugars in the putative binding site of the P2Y14 receptor was performed
with MCMM implemented in MacroModel 9.0 software.40
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Initially, an MCMM search was performed only on the glucose ring of UDPG. The atoms
located within 8 Å from the ring were used as a shell. The bond between carbon atoms at
positions 2 and 3 of the glucose ring was “opened” during the conformational search. The
following parameters were used: MMFFs force field, water was used as an implicit solvent,
a maximum of 1000 iterations of the Polak-Ribier Conjugate Gradient minimization method
was used with a convergence threshold of 0.05 kJ·mol−1·Å−1, the number of conformational
search steps = 1000, the energy window for saving structures = 1000 kJ·mol−1. An MCMM
search then was performed on the entire ligand and all residues located within 6 Å from
UDPG using a shell of residues located within 2 Å. Two ligand-receptor complexes with
different conformation of the hexose ring were subjected to MCMM calculations. The one
hundred steps of conformational search and an energy window for saving structures of 100
kJ·mol−1 were used. This protocol was applied to MCMM calculations performed for all
other studied ligands.
Molecular Docking—To prove the binding mode obtained for UDPG at the P2Y14
receptor an additional independent docking study was performed with the Glide program of
MacroModel package40. Our initial model of the P2Y14 receptor obtained after 20 ns of MD
simulation was utilized for automatic docking of UDPG. The receptor grid generation was
performed for the box with a side of 46Å with a center in the centroid of Lys171, Arg253,
and Lys277. Extra precision (XP) of docking was used. The flexibility of a ligand was
allowed. The conformations of the sidechains of residues located within 6 Å from UDPG
were refined by 100 steps of MCMM calculations with an energy window for saving
structures of 100 kJ·mol−1. The model obtained after this refinement was used for a Glide-
aided automatic docking of all other ligands.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Activation by potent agonists 13 (A) and 15 (B) of phospholipase C in COS-7 cells
expressing both the human P2Y14 receptor and an engineered Gα-q/i protein that allows the
Gi-coupled receptor to stimulate inositol phosphate hydrolysis by phospholipase C.
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Possible conformations of the hexose ring of UDPG.
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The molecular model of the human P2Y14 receptor obtained after 20 ns of molecular
dynamics simulation. A centroid of Lys171, Arg253, and Lys277 (red sphere) was used as a
center of the box for molecular docking of UDPG.
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Molecular model of the P2Y14-compound 15 complex. A rhodopsin-based molecular model
of the human P2Y14 receptor11,31 was refined using 20 ns molecular dynamics (MD)
simulation in the phospholipid bilayer. The complex obtained after the automatic docking of
15 was used as a starting point for a Monte Carlo Multiple Minimum (MCMM)
conformational search analysis of the ligand inside the putative binding site of the P2Y14
receptor.
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The fructose moiety of 26 docked within the binding site of the human P2Y14 receptor.
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Synthesis of UDPG analogues substituted on the ribose moiety or the 2 position of the uracil
moiety. Reagents and conditions: (a) (i) POCl3, Proton Sponge, PO(OMe)3, 0 °C, (ii) 0.2 M
triethylammonium bicarbonate, rt; (b) CF3CO2Et, DIEA, DMF, rt; (c) (i) 1,1′-
carbonyldiimidazole, DMF, rt, (ii) Et3N 5% in H2O/MeOH 1/1, rt, (iii) glucose-1-
monophosphate tributylammonium salt, DMF, rt; (d) H2, Pd/C, MeOH, rt; (e) (i)
morpholine, DCC, t-BuOH, H2O, reflux, (ii) glucose-1-monophosphate tributylammonium
salt, DMF, rt.
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Synthesis of UDPG analogues substituted on the 4 or 5 position of the uracil moiety.
Reagents and conditions: (a) (i) 1,1′-carbonyldiimidazole, DMF, rt, (ii) Et3N 5% in H2O/
MeOH 1/1, rt, (iii) glucose-1-monophosphate tributylammonium salt, DMF, rt; (b) (i) 0.25
M NaOH, H2O, MeOH, rt, (ii) iodomethane, DMF, rt.
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Synthesis of an (S)-methanocarba analogue of 2′-deoxy-UDPG. Reagents and conditions:
(a) (i) 1,1′-carbonyldiimidazole, DMF, rt, (ii) Et3N 5% in H2O/MeOH 1/1, rt, (iii)
glucose-1-monophosphate tributylammonium salt, DMF, rt.
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Structures of three naturally-occurring UDP-sugars (1, 2, and 4a) and related derivatives that
activate the P2Y14 receptor.
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Table 1
In vitro pharmacological data for UDP-glucose, 1, and its analogues in the stimulation of phospholipase C in
COS-7 cells expressing recombinant human P2Y14 receptors






















5 2′-deoxy R2 = H NE
6 2′-deoxy-2′
-azido
R2 = N3 NE
7 2′-deoxy-2′-
amino





R2, R3 = cyclic-
NHCOO
NE




R2 = CH3OCOO, NE
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13b 4-thio X1 = S 0.29 ± 0.16e
14 4-methylthio X1 = SCH3 >10c
15b 2-thio X2 = S 0.049 ± 0.002e
16 5-iodo R1 = I NE
17 5-azido R1 = N3 NE
18 5-amino R1 = NH2 NE
19 Base = C NE
20 Base = A NE
21 Base = G NE
Base-and ribose modified
22 2′-deoxy-C R2 = H,
X1 = NH
NE
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25 UDP-inositol 1.88 ± 1.1e
26 UDP-fructose 0.88 ± 0.21e








COS-7 cells were transiently transfected with expression vectors for both the human P2Y14 receptor and an engineered Gα-q/i protein that allows
coupling of Gi-coupled receptors to activation of phospholipase C.35 Agonist potencies were calculated using a four-parameter logistic equation
and the GraphPad software package (GraphPad, San Diego, CA). EC50 values (mean ± standard error) represent the concentration at which 50% of
the maximal effect is achieved. N = 3, unless noted.
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b
13, MRS2670; 15, MRS2690 (n = 4).
c
Less than or equal to 50% of the maximal effect at 10 µM.
d
Exhibited a maximal effect somewhat less than 1 in some but not all experiments.
e
100% of the maximal effect of 1 was achieved.
f
Compound 12 =
NE - no effect at 100 µM.
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